Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East
Journal of Proteome Research · 02.01.2026 · 25 (1) · 21-40
DOI: 10.1021/acs.jproteome.5c00949 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Proteome Research, online erschienen am 12.12.2025. Verfasst von Lubna Therachiyil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Institute, Hamad Medical Corporation, Doha 3050, Qatar. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Proteomics, Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 232 Literaturangaben. Gefördert von: Qatar National Library.
Abstract (Originalsprache)
Proteomics has become a transformative tool in oncology, offering unique opportunities for early detection, diagnosis, and cancer stratification. By enabling large-scale analysis of protein expression, interactions, and post-translational modifications, proteomics facilitates the discovery of clinically relevant biomarkers that reflect the dynamic molecular state of disease. These biomarkers, often detectable in easily accessible body fluids like blood, urine, or saliva, serve as minimally invasive "liquid biopsies" capable of identifying malignancies at asymptomatic stages. The integration of high-resolution mass spectrometry with advanced computational methods, including machine learning and network-based analytics, has accelerated the identification of reliable biomarker panels for cancer prediction, monitoring, and treatment response. Proteomics not only complements genomic and transcriptomic data but also provides a functional view of cellular states, bridging the gap between genotype and phenotype. This is especially important for customizing personalized treatment plans based on tumor-specific protein profiles, thus reducing the off-target effects of traditional therapies. Furthermore, proteomics plays a crucial role in finding cancer-related mechanisms, such as immune evasion, angiogenesis, and metastatic progression. Although proteomics-based biomarker discovery holds critical promise for cancer diagnosis and precision medicine, substantial translational challenges remain. These include assay standardization, sample accessibility from a regional biobank, regulatory obstacles, cross-population validation, and the integration of discoveries into clinical workflows. In this perspective, we offer a comprehensive overview of the latest progress in proteomics-driven cancer biomarker discovery, with a particular focus on its translational potential in early detection and precision oncology. The increasing incidence of cancer in the Middle East is highlighted, necessitating an urgent expansion of research into population-specific biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Institute, Hamad Medical Corporation, Doha 3050, Qatar.
- Metabolic and Mendelian Disorders Clinical Research Program, Precision OMICs Research & Translational Science, Sidra Medicine, Doha 26999, Qatar.
- Department of Biosciences, Integral University, Lucknow, Uttar Pradesh 226026, India.
ORCID-Profile: Ajaz A Bhat, Shahab Uddin
Förderung
- Qatar National Library
Zitieren
APA
Therachiyil, L., Surendranath, A., Anand, A., Dogan Sahin, R., Akil, A. S. A., Bhat, A. A., & Uddin, S. (2026). Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East. Journal of Proteome Research, 25(1), 21-40. https://doi.org/10.1021/acs.jproteome.5c00949
Vancouver
Therachiyil L, Surendranath A, Anand A, Dogan Sahin R, Akil ASA, Bhat AA, et al. Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East. Journal of Proteome Research. 2026;25(1):21-40. doi:10.1021/acs.jproteome.5c00949
BibTeX
@article{Therachiyil2026,
author = {Therachiyil, Lubna and Surendranath, Anju and Anand, Anjana and Dogan Sahin, Rumeysa and Akil, Ammira S Al-Shabeeb and Bhat, Ajaz A and Uddin, Shahab},
title = {Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East},
journal = {Journal of Proteome Research},
year = {2026},
volume = {25},
number = {1},
pages = {21--40},
doi = {10.1021/acs.jproteome.5c00949}
}
EUVIMED